JO3371B1 - ناهضات مستقبل فاسوبريسين 2 - Google Patents

ناهضات مستقبل فاسوبريسين 2

Info

Publication number
JO3371B1
JO3371B1 JOP/2014/0234A JOP20140234A JO3371B1 JO 3371 B1 JO3371 B1 JO 3371B1 JO P20140234 A JOP20140234 A JO P20140234A JO 3371 B1 JO3371 B1 JO 3371B1
Authority
JO
Jordan
Prior art keywords
vasopressin
receptor agonists
nocturia
foregoing
methods
Prior art date
Application number
JOP/2014/0234A
Other languages
English (en)
Inventor
Riviere Pierre
Wisniewski Kazimierz
Schteingart Claudio
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3371B1 publication Critical patent/JO3371B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)

Abstract

ناهضات مستقبلات فاسوبريسين-2، تراكيب دوائية منها وطرق لاستخدام ما سبق ذكره لعلاج مرض السكري الكاذب و سلس البول الليلي الابتدائي وكثرة التبول أثناء الليل.
JOP/2014/0234A 2013-07-26 2014-07-24 ناهضات مستقبل فاسوبريسين 2 JO3371B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361859024P 2013-07-26 2013-07-26
US201461952073P 2014-03-12 2014-03-12

Publications (1)

Publication Number Publication Date
JO3371B1 true JO3371B1 (ar) 2019-03-13

Family

ID=51398870

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0234A JO3371B1 (ar) 2013-07-26 2014-07-24 ناهضات مستقبل فاسوبريسين 2

Country Status (27)

Country Link
US (2) US10131692B2 (ar)
EP (1) EP3024829B1 (ar)
JP (1) JP6387095B2 (ar)
KR (1) KR102198130B1 (ar)
CN (1) CN105492441B (ar)
AU (1) AU2014292860B2 (ar)
BR (1) BR112016000436B1 (ar)
CA (1) CA2919208A1 (ar)
DK (1) DK3024829T3 (ar)
EA (1) EA029392B1 (ar)
ES (1) ES2656039T3 (ar)
HR (1) HRP20180009T1 (ar)
HU (1) HUE035252T2 (ar)
IL (1) IL243730B (ar)
JO (1) JO3371B1 (ar)
LT (1) LT3024829T (ar)
MX (1) MX363355B (ar)
MY (1) MY183429A (ar)
PH (1) PH12016500044A1 (ar)
PL (1) PL3024829T3 (ar)
PT (1) PT3024829T (ar)
RS (1) RS56604B1 (ar)
SG (1) SG11201600031RA (ar)
SI (1) SI3024829T1 (ar)
TW (1) TWI640542B (ar)
WO (1) WO2015013690A1 (ar)
ZA (1) ZA201600145B (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
IL313083A (en) 2016-10-21 2024-07-01 Amryt Endo Inc Terlipressin compositions and their methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE399252B (sv) * 1976-05-24 1978-02-06 Ferring Ab Forfarande for framstellnign av antidiuretiskt verkande desamino-asparagin Ÿ4-d-argininŸ8-vasopressin
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DK153883A (da) 1982-04-20 1983-10-21 Ceskoslovenska Akademie Ved Vasopressin-analoge
SE501677C2 (sv) * 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
CZ292131B6 (cs) 2000-02-16 2003-08-13 Ústav organické chemie a biochemie AV ČR Synthetické analogy Desmopressinu chráněné v C-terminální sekvenci proti karboxyamidasovému štěpení
JP6131120B2 (ja) * 2013-06-19 2017-05-17 株式会社パイオラックス コネクタ

Also Published As

Publication number Publication date
NZ716342A (en) 2021-03-26
ZA201600145B (en) 2020-01-29
HRP20180009T1 (hr) 2018-02-09
MX2016000525A (es) 2016-04-07
SI3024829T1 (en) 2018-01-31
EP3024829A1 (en) 2016-06-01
HUE035252T2 (en) 2018-05-02
US10745443B2 (en) 2020-08-18
MY183429A (en) 2021-02-18
WO2015013690A1 (en) 2015-01-29
EP3024829B1 (en) 2017-11-08
PH12016500044B1 (en) 2016-03-28
TWI640542B (zh) 2018-11-11
LT3024829T (lt) 2017-12-27
US10131692B2 (en) 2018-11-20
ES2656039T3 (es) 2018-02-22
JP6387095B2 (ja) 2018-09-05
KR20160034943A (ko) 2016-03-30
BR112016000436B1 (pt) 2022-07-05
RS56604B1 (sr) 2018-02-28
AU2014292860B2 (en) 2017-10-05
IL243730B (en) 2019-09-26
TW201536815A (zh) 2015-10-01
PL3024829T3 (pl) 2018-04-30
EA029392B1 (ru) 2018-03-30
BR112016000436A2 (ar) 2017-07-25
HK1218647A1 (en) 2017-03-03
PH12016500044A1 (en) 2016-03-28
PT3024829T (pt) 2017-12-18
US20190194257A1 (en) 2019-06-27
SG11201600031RA (en) 2016-02-26
CA2919208A1 (en) 2015-01-29
US20150307555A1 (en) 2015-10-29
IL243730A0 (en) 2016-04-21
CN105492441B (zh) 2019-09-10
EA201690219A1 (ru) 2016-11-30
KR102198130B1 (ko) 2021-01-05
MX363355B (es) 2019-03-21
JP2016527255A (ja) 2016-09-08
CN105492441A (zh) 2016-04-13
DK3024829T3 (en) 2017-12-04
AU2014292860A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CL2017001288A1 (es) Agonistas parciales del receptor de insulina
EA201290626A1 (ru) Устройство
GB201017345D0 (en) Receptor antagonists
PH12016500739B1 (en) Inhibitors of the fibrolast growth factor receptor
PH12016500316A1 (en) Improved adenovirus formulations
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
ZA202507394B (en) Semaglutide in cardiovascular conditions
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EP3089432A4 (en) List generating device, list distribution device, received call processing device and program
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
CL2014001871A1 (es) Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
CA3013532A1 (en) Liraglutide in cardiovascular conditions
PT3004058T (pt) Compostos inibidores da acetilcolinesterase e agonistas dos receptores serotonérgicos 5ht4, com efeito estimulador de memória, métodos para a preparação destes e composições farmacêuticas contendo os mesmos
PH12016500044B1 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия
辛迪嘉 SUV8
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"
MY163393A (en) Pharmaceutical formulations of telmisartan and process for preparing the same
HK1233666A1 (en) Fgf21 receptor agonists and uses thereof
IN2013CH00453A (ar)
UA78463U (uk) Матеріал для термопар і термоелементів